-DOCSTART- -X- O
Influenza -X- _ B-Patient
viruses -X- _ I-Patient
cause -X- _ O
respiratory -X- _ O
tract -X- _ O
infections -X- _ O
that -X- _ O
in -X- _ O
patients -X- _ O
with -X- _ O
underlying -X- _ O
lung -X- _ O
diseases -X- _ O
such -X- _ O
as -X- _ O
chronic -X- _ O
obstructive -X- _ O
pulmonary -X- _ O
disease -X- _ O
( -X- _ O
COPD -X- _ O
) -X- _ O
are -X- _ O
associated -X- _ O
with -X- _ O
exacerbations -X- _ O
and -X- _ O
excess -X- _ O
morbidity -X- _ O
and -X- _ O
mortality. -X- _ O
Typically -X- _ O
, -X- _ O
influenza -X- _ O
B -X- _ O
is -X- _ O
associated -X- _ O
with -X- _ O
relatively -X- _ O
mild -X- _ O
, -X- _ O
local -X- _ O
outbreaks -X- _ O
, -X- _ O
whereas -X- _ O
influenza -X- _ O
A -X- _ O
is -X- _ O
the -X- _ O
cause -X- _ O
of -X- _ O
world-wide -X- _ O
pandemics. -X- _ O
Upon -X- _ O
infection -X- _ O
, -X- _ O
two -X- _ O
antigens -X- _ O
present -X- _ O
on -X- _ O
the -X- _ O
viral -X- _ O
surface -X- _ O
, -X- _ O
hemagglutinin -X- _ O
and -X- _ O
neuraminidase -X- _ O
result -X- _ O
in -X- _ O
human -X- _ O
immunity -X- _ O
, -X- _ O
but -X- _ O
since -X- _ O
many -X- _ O
subtypes -X- _ O
of -X- _ O
these -X- _ O
antigens -X- _ O
exist -X- _ O
that -X- _ O
vary -X- _ O
over -X- _ O
time -X- _ O
, -X- _ O
immunity -X- _ O
in -X- _ O
the -X- _ O
population -X- _ O
is -X- _ O
blunted. -X- _ O
Vaccination -X- _ O
is -X- _ O
advocated -X- _ O
in -X- _ O
high-risk -X- _ B-Comparision
groups -X- _ I-Comparision
including -X- _ I-Comparision
patients -X- _ I-Comparision
with -X- _ I-Comparision
underlying -X- _ I-Comparision
( -X- _ I-Comparision
lung -X- _ I-Comparision
) -X- _ I-Comparision
diseases -X- _ I-Comparision
and -X- _ O
in -X- _ O
the -X- _ O
elderly -X- _ O
, -X- _ O
and -X- _ O
needs -X- _ O
to -X- _ O
be -X- _ O
repeated -X- _ O
annually -X- _ O
with -X- _ O
vaccines -X- _ O
expected -X- _ O
to -X- _ O
cover -X- _ O
the -X- _ O
expected -X- _ O
change -X- _ O
in -X- _ O
viral -X- _ O
antigenicity. -X- _ O
When -X- _ O
started -X- _ O
early -X- _ O
, -X- _ O
antiviral -X- _ O
drugs -X- _ O
, -X- _ O
especially -X- _ O
neuraminidase-inhibitors -X- _ O
can -X- _ O
be -X- _ O
prescribed -X- _ O
in -X- _ O
adjunct -X- _ O
to -X- _ O
nonspecific -X- _ O
interventions -X- _ O
in -X- _ O
an -X- _ O
attempt -X- _ O
to -X- _ O
shorten -X- _ O
disease -X- _ O
duration -X- _ O
and -X- _ O
to -X- _ O
prevent -X- _ O
complications -X- _ O
in -X- _ O
case -X- _ O
of -X- _ O
an -X- _ O
influenza -X- _ O
infection. -X- _ O
Currently -X- _ O
, -X- _ O
the -X- _ O
effectiveness -X- _ B-Outcome
of -X- _ I-Outcome
antiviral -X- _ I-Outcome
drugs -X- _ I-Outcome
specifically -X- _ I-Outcome
in -X- _ I-Outcome
patients -X- _ I-Outcome
with -X- _ I-Outcome
COPD -X- _ I-Outcome
has -X- _ O
not -X- _ O
been -X- _ O
proven -X- _ O
. -X- _ O

